Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
10.1245/s10434-006-9101-1
Annals of Surgical Oncology 13:1529-1537 (2006)
© 2006 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yan, T. D.
Right arrow Articles by Morris, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yan, T. D.
Right arrow Articles by Morris, D. L.

Original Article

Percutaneous Radiofrequency Ablation of Pulmonary Metastases from Colorectal Carcinoma: Prognostic Determinants for Survival

Tristan D. Yan, BSc (Med), MBBS1, Julie King, MPH1, Adrian Sjarif, MBBS1, Derek Glenn, FRACR2, Karin Steinke, MD1,2 and David L. Morris, MD, PhD1

1 Department of Surgery, University of New South Wales, St. George Hospital, Sydney, New South Wales 2217, Australia
2 Department of Radiology, University of New South Wales, St. George Hospital, Sydney, New South Wales 2217, Australia

Correspondence: Address correspondence and reprint requests to: Tristan D. Yan, BSc (Med), MBBS; E-mail: Tristan.Yan{at}unsw.edu.au

Background: Preliminary results have shown that percutaneous radiofrequency ablation (RFA) may play a useful role in patients with inoperable lung tumors. This series evaluated the prognostic features for survival in nonsurgical candidates who underwent percutaneous RFA of pulmonary metastases from colorectal carcinoma.

Methods: Fifty-five patients not suitable for surgery underwent percutaneous RFA for colorectal pulmonary metastases. All clinical and treatment-related data were collected prospectively. The primary end point of the study was overall survival, defined from the time of RFA intervention. Univariate and multivariate analyses were performed to identify statistically significant prognostic parameters for overall survival.

Results: The overall median survival was 33 months (range, 4–40 months), with actuarial 1-, 2-, and 3-year survival of 85%, 64%, and 46%, respectively. Univariate analysis demonstrated that largest size of lung metastasis (P < .001), location of lung metastases (P = .032), and repeat percutaneous RFA for pulmonary recurrence (P = .024) were statistically significant for overall survival. Multivariate analysis demonstrated that largest size of lung metastasis >3 cm was independently associated with a reduced overall survival (P = .003).

Conclusions: Percutaneous lung RFA may play a useful role in nonsurgical candidates with colorectal pulmonary metastases. However, the survival benefit of this interventional procedure for patients with a pulmonary metastasis >3 cm was limited.

Key Words: Radiofrequency ablation • Pulmonary metastases • Colorectal carcinoma




This article has been cited by other articles:


Home page
 Ann. Surg. Oncol.Home page
J. C. Zhu, T. D. Yan, and D. L. Morris
A Systematic Review of Radiofrequency Ablation for Lung Tumors
Ann. Surg. Oncol., June 1, 2008; 15(6): 1765 - 1774.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
H. C. Fernando
Radiofrequency Ablation to Treat Non-Small Cell Lung Cancer and Pulmonary Metastases
Ann. Thorac. Surg., February 1, 2008; 85(2): S780 - S784.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the Society of Surgical Oncology.